Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib
about
European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemiaSafety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia.Managing chronic myeloid leukemia patients intolerant to tyrosine kinase inhibitor therapy.Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failureOutcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemiaTargeted therapy for patients with chronic myeloid leukemia: clinical trial experience and challenges in inter-trial comparisons.Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patients.Management of adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukemia.Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 study.Evaluating the Impact of a Switch to Nilotinib on Imatinib-Related Chronic Low-Grade Adverse Events in Patients With CML-CP: The ENRICH Study.Safety and efficacy of nilotinib in routine clinical practice in patients with chronic myeloid leukemia in chronic or accelerated phase with resistance or intolerance to imatinib: results from the NOVEL study.
P2860
Q26749324-581031E8-0D29-43EB-81C1-9A3A916E782EQ35008618-A42EC406-CF74-419F-9424-BD7C1E56AC18Q36355098-86D93B20-BAE2-4C12-ACAA-D56751F510A9Q37027759-1E471D4B-3EFA-4426-AC90-61C5ACDA5C5AQ37117967-65BB2D91-2CF1-4E92-BDBE-DA5FF31C0F97Q37965564-7D26E5EB-7E1A-4C90-917C-BFC146BD41E5Q38095848-539A9DE6-F055-45F7-A759-641DC9FE8A5BQ38392673-8DE76A19-D50B-4ECD-A84F-1108C62A606BQ38392679-5C908C59-ACBF-42B0-B43B-B4502B163874Q41402735-2152C964-605A-4E75-9C20-7A63BCE2CDF0Q42395994-693E3D5C-10E6-429C-AC3E-8CB255747A58Q52659302-CE608FCA-23F6-4415-A3DE-3AF911DCA3D2
P2860
Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Minimal cross-intolerance with ...... who are intolerant to imatinib
@ast
Minimal cross-intolerance with ...... who are intolerant to imatinib
@en
type
label
Minimal cross-intolerance with ...... who are intolerant to imatinib
@ast
Minimal cross-intolerance with ...... who are intolerant to imatinib
@en
prefLabel
Minimal cross-intolerance with ...... who are intolerant to imatinib
@ast
Minimal cross-intolerance with ...... who are intolerant to imatinib
@en
P2093
P2860
P50
P1433
P1476
Minimal cross-intolerance with ...... who are intolerant to imatinib
@en
P2093
Francis J Giles
Javier Pinilla-Ibarz
Kathryn Gillis
Philipp D le Coutre
Richard C Woodman
Rick E Blakesley
P2860
P304
P356
10.1182/BLOOD-2010-11-318949
P407
P50
P577
2011-04-05T00:00:00Z